Avastin approved for cervical cancer
BASEL, Switzerland—Roche’s Avastin (bevacizumab) has received U.S. Food and Drug Administration approval in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. This marks the fifth distinct tumor type Avastin is approved to treat in the United States; the drug is also approved for the treatment of advanced colorectal cancer, non-small cell lung cancer, kidney cancer and progressive glioblastoma following prior therapy.
“With this approval, women with advanced cervical cancer now have the option of Avastin plus chemotherapy to help them live longer than with chemotherapy alone,” said Dr. Sandra Horning, chief medical officer and head of global product development. “Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, and until today, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread.”